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Abstract. 
 
Muscle ﬁbers attach to laminin in the basal
lamina using two distinct mechanisms: the dystrophin gly-
coprotein complex and the 
 
a
 
7
 
b
 
1 integrin. Defects in these
 
linkage systems result in Duchenne muscular dystro-
phy (DMD), 
 
a
 
2 laminin congenital muscular dystrophy,
sarcoglycan-related muscular dystrophy, and 
 
a
 
7 integrin
congenital muscular dystrophy. Therefore, the molecular
continuity between the extracellular matrix and cell
cytoskeleton is essential for the structural and functional
 
integrity of skeletal muscle. To test whether the 
 
a
 
7
 
b
 
1
 
 in-
tegrin can compensate for the absence of dystrophin,
 
we expressed the rat 
 
a
 
7 chain in 
 
mdx/utr
 
2
 
/
 
2
 
 mice that
 
lack both dystrophin and utrophin. These mice
 
 
 
develop a
severe muscular dystrophy highly akin to that in DMD,
and they also die prematurely. Using the muscle creatine
kinase promoter, expression of the 
 
a
 
7BX2 integrin chain
 
was increased 2.0–2.3-fold in 
 
mdx/utr
 
2
 
/
 
2
 
 mice. Concomi-
tant with the increase in the 
 
a
 
7 chain, its heterodimeric
partner, 
 
b
 
1D, was also increased in the transgenic animals.
Transgenic expression of the 
 
a
 
7BX2 chain in the
 
mdx/utr
 
2
 
/
 
2
 
 mice extended their longevity by threefold,
reduced kyphosis and the development of muscle dis-
ease, and maintained mobility and the structure of the
 
neuromuscular junction. Thus, bolstering 
 
a
 
7
 
b
 
1
 
 integrin–
mediated association of muscle cells with the extracellular
matrix alleviates many of the symptoms of disease
observed in 
 
mdx/utr
 
2
 
/
 
2
 
 mice and compensates for the
absence of the dystrophin- and utrophin-mediated linkage
systems. This suggests that enhanced expression of the
 
a
 
7
 
b
 
1
 
 integrin may provide a novel approach to treat
DMD and other muscle diseases that arise due to defects
in the dystrophin glycoprotein complex. A video that con-
trasts kyphosis, gait, joint contractures, and mobility in
 
mdx/utr
 
2
 
/
 
2
 
 and 
 
a
 
7BX2-mdx/utr
 
2
 
/
 
2 
 
mice can be accessed
at http://www.jcb.org/cgi/content/full/152/6/1207.
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Introduction
 
The defective association of skeletal and cardiac muscle
with their surrounding basal lamina underlies the patholo-
gies associated with a variety of muscular dystrophies and
cardiomyopathies (Matsumura and Campbell, 1994; Ha-
yashi et al., 1998; Lim and Campbell, 1998). Duchenne
muscular dystrophy (DMD)
 
1
 
 is a congenital X-linked my-
opathy that is caused by a lack of the dystrophin protein
and affects approximately 1 in 3,300 males. Patients with
DMD experience progressive muscle deterioration and
debilitation that severely restricts mobility. Death due to
cardiac and respiratory failure usually occurs in the second
decade of life.
Mutations in the dystrophin gene result in a lack of dys-
trophin, a 427-kD protein localized at the cytoplasmic side
of the plasma membrane of skeletal and cardiac muscle
cells (Monaco et al., 1986; Matsumura and Campbell,
1994; Campbell, 1995). In association with dystroglycans,
syntrophins, and sarcoglycans, dystrophin links the cell
cytoskeleton to laminin in the extracellular matrix. In the
absence of one or more components of the dystrophin
linkage system, the association of fibers with the surround-
ing basal lamina is compromised, leading to the myopathy
observed. Thus, the molecular continuity between the ex-
tracellular matrix and the cell cytoskeleton is essential for
the structural and functional integrity of muscle.
 
The integrins are 
 
ab
 
 heterodimeric receptors that bind ex-
tracellular matrix proteins and interact with the cell cytoskel-
eton (Hynes, 1992). The 
 
a
 
7
 
b
 
1 integrin is a laminin receptor
on skeletal and cardiac muscle (von der Mark et al., 1991;
Song et al., 1992) and serves as a transmembrane link be-
tween the basal lamina and muscle fibers. Multiple isoforms
of the 
 
a
 
7 and 
 
b
 
1 chains are generated by developmentally
regulated RNA splicing, resulting in a family of receptors
 
J
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with diverse structures and functions (for reviews see
Hodges and Kaufman, 1996; Burkin and Kaufman, 1999).
The 
 
a
 
7 integrin chain is encoded by a single autosomal
gene on human chromosome 12q13 (Wang et al., 1995).
Three alternative cytoplasmic domains (
 
a
 
7A, 
 
a
 
7B, and
 
a
 
7C) and two extracellular domain variants (X1 and X2)
of the protein have been identified (Collo et al., 1993;
Song et al., 1993; Ziober et al., 1993). Four additional al-
ternatively spliced isoforms of the extracellular domain
have been predicted by nucleotide sequence analysis (Le-
ung et al., 1998; Vignier et al., 1999).
The 
 
b
 
1 chain cytoplasmic domain also undergoes devel-
opmentally regulated alternative splicing. 
 
b
 
1A is the most
common isoform of the 
 
b
 
1 chain and is expressed in a wide
variety of tissues including replicating myoblasts. The al-
ternative 
 
b
 
1D form is generated upon differentiation of
myoblasts to myofibers (van der Flier et al., 1995; Zhid-
kova et al., 1995; Belkin et al., 1996, 1997).
Mutations in the genes that encode the many components
of the dystrophin glycoprotein complex cause a variety of
muscular dystrophies. Mutations in the 
 
a
 
7 gene also cause
congenital myopathies (Hayashi et al., 1998). Thus, both the
integrin- and dystrophin-mediated transmembrane linkage
systems contribute to the functional integrity of skeletal
muscle. Interestingly, there is an increase in the amount of
 
a
 
7 transcript and protein in DMD patients and 
 
mdx
 
 mice
(the mouse model that has a mutation in its dystrophin
gene) (Hodges et al., 1997). This led us to suggest that en-
hanced expression of the integrin may partially compensate
for the absence of the dystrophin glycoprotein complex
(Hodges et al., 1997; Burkin and Kaufman, 1999).
Utrophin, a protein homologous to dystrophin, is also
increased in DMD patients and 
 
mdx
 
 mice (Law et al.,
1994; Pons et al., 1994). Utrophin associates with many of
the same proteins as dystrophin and further increasing
utrophin may, in part, also compensate for the absence of
dystrophin (Tinsley et al., 1996).
Although DMD patients (Monaco et al., 1986) and 
 
mdx
 
mice (Bulfield et al., 1984; Sicinski et al., 1989) both lack
dystrophin, the pathology that develops in the 
 
mdx
 
 mouse is
much less severe than that observed in humans. The differ-
ences in the extent of pathology may be due to several fac-
tors, including the enhanced expression and altered localiza-
tion of utrophin (Law et al., 1994; Pons et al., 1994) and the
 
a
 
7 integrin chain (Hodges et al., 1997) in 
 
mdx
 
 mice. In addi-
tion, differences in utilization of skeletal muscles by humans
compared with mice in captivity may also contribute to the
decreased level of pathology seen in 
 
mdx
 
 mice. In contrast,
 
mdx/utr
 
2
 
/
 
2
 
 mice lack both dystrophin and utrophin and
have a phenotype that is similar to that seen in DMD pa-
tients. These double mutant mice develop severe progres-
sive muscular dystrophy and die prematurely between 4 and
20 wk of age (Deconinck et al., 1997b; Grady et al., 1997b).
To explore the hypothesis that enhanced expression of
the 
 
a
 
7
 
b
 
1 integrin may compensate for the absence of the
dystrophin glycoprotein complex and reduce the develop-
ment of severe muscle disease, transgenic mice were made
that express the rat 
 
a
 
7 chain. We report that 
 
mdx/utr
 
2
 
/
 
2
 
mice with enhanced expression of the 
 
a
 
7BX2 chain iso-
form show greatly improved longevity and mobility com-
pared with nontransgenic 
 
mdx/utr
 
2
 
/
 
2
 
 mice. Transgenic
mice maintained weight and had reduced spinal curvature
 
(kyphosis) and joint contractures. Transgenic expression
of the 
 
a
 
7BX2 chain also reduced the degree of mononu-
clear cell infiltration and expression of fetal myosin heavy
chain (fMyHC) in muscle fibers. Together these results
show that enhanced expression of 
 
a
 
7BX2
 
b
 
1D integrin sig-
nificantly reduces the development of muscular dystrophy.
 
Materials and Methods
 
Muscle Creatine Kinase-
 
a
 
7BX2 Integrin Construct
 
The cDNA encoding the rat 
 
a
 
7BX2 integrin isoform was cloned into
pBK-RSV vector (Stratagene) downstream of the 3.3-kb mouse muscle
creatine kinase (MCK) promoter and the mouse 
 
a
 
7 integrin cell surface
localization signal sequence using the restriction sites AatII and KpnI.
The MCK promoter was provided by Dr. Stephen Hauschka (University
of Washington, Seattle, WA). The construct was verified by DNA se-
quencing. Previous studies have shown that the MCK promoter is only ac-
tive in heart and skeletal muscle (Jaynes et al., 1986; Johnson et al., 1989;
Shield et al., 1996). The expression and functionality of the MCK-
 
a
 
7BX2
integrin construct were verified by transfecting C2C12 myoblasts (Burkin
et al., 1998, 2000).
 
Production of Transgenic mdx/utr
 
2
 
/
 
2
 
 Mice
 
The MCK-
 
a
 
7BX2 construct was gel purified. 
 
mdx/utr
 
1
 
/
 
2
 
 female mice
were superovulated, mated to 
 
mdx/utr
 
1
 
/
 
2
 
 male mice, and fertilized oo-
cytes were collected. The MCK-
 
a
 
7BX2 construct was microinjected into
male pronuclei, and injected oocytes were placed into pseudopregnant
mice at the University of Illinois Transgenic Animal Facility. Resulting
pups were weaned at 3 wk of age, and genomic DNA was isolated from
0.5-cm tail clips using a DNA isolation kit (Promega). Primers (MCK1, 5
 
9
 
-
caagctgcacgcctgggtcc-3
 
9
 
; and AATII, 5
 
9
 
-ggcacccatgacgtccagattgaag-3
 
9
 
),
used to amplify between the MCK promoter and the 
 
a
 
7 integrin cDNA,
produced a 455-bp fragment only in transgenic mice. Transgenic 
 
mdx/utr
 
1
 
/
 
2
 
male mice were bred with 
 
mdx/utr
 
1
 
/
 
2
 
 female mice to produce transgenic
 
a
 
7BX2-mdx/utr
 
2
 
/
 
2
 
 offspring. The
 
 mdx/utr
 
1
 
/
 
2
 
 mice (Grady et al., 1997b)
used in these experiments were provided by Dr. Joshua Sanes (Washing-
ton University, St. Louis, MO).
The 
 
mdx
 
 mutation was screened by the amplification-resistant muta-
tion system described by Amalfitano and Chamberlain (1996). A new for-
ward primer (Int22-306F, 5
 
9
 
-catagttattaatgcatagatattcag-3
 
9
 
) upstream of
the 
 
mdx 
 
mutation site was used to yield a larger, 275-bp band. The status
of the utrophin gene was analyzed by PCR using the primers 553, 554, and
22803 described previously by Grady et al. (1997a). C57BL6 
 
3 
 
SJ6 mice
were used as wild-type controls.
 
Antibodies and Reagents
 
For immunofluorescence analysis, the mouse monoclonal antibody O26
was used to detect the transgenic rat 
 
a
 
7 chain. Polyclonal anti-
 
a
 
7CDA
(345) and anti-
 
a
 
7CDB (347) were used in Western blots to detect the 
 
a
 
7A
and 
 
a
 
7B cytoplasmic domains, respectively (Song et al., 1993; Martin et
al., 1996). The amino acid sequences of the mouse and rat 
 
a
 
7 chain cyto-
plasmic domains are identical, thus these antisera will detect both species
with equal affinity. Peptides used to make these polyclonal antibodies
were used as blocking controls. Rabbit polyclonal antibodies to the cyto-
plasmic domains of the 
 
b
 
1A and 
 
b
 
1D integrin chains were provided by
Dr. W.K. Song (K-JIST, Kwang-ju, Korea; Kim et al., 1999). Dystrophin
was detected using an antidystrophin monoclonal antibody (MANDRA1)
(Sigma-Aldrich). Antiutrophin monoclonal antibody (NCL-DRP2) was
purchased from Novacastra. The anti-fMyHC monoclonal antibody 47A
was a gift from Dr. Peter Merrifield (University of Western Ontario, Lon-
don, Ontario, Canada). The anti-creatine kinase monoclonal antibody was
obtained from ADI Diagnostics. Acetylcholine receptor (AChR) clus-
ters were detected with rhodamine-labeled 
 
a
 
-bungarotoxin (Molecular
Probes). FITC-labeled donkey anti–mouse and anti–rabbit antibodies
were purchased from Jackson ImmunoResearch Laboratories.
 
Western Blot Analysis
 
Samples of muscle tissue were extracted in 200 mM octyl-
 
b
 
-
 
D
 
-glucopy-
ranoside or 1% NP-40 in 50 mM Tris-HCl, pH 7.4, 2 mM PMSF, 1:200 di-
lution of Protease Cocktail Set III (Calbiochem), 1 mM CaCl2, and 1 mMBurkin et al. Integrin-mediated Alleviation of Muscular Dystrophy 1209
MgCl2 at 48C for 1 h. The supernatants were collected and protein concen-
trations were determined using Bradford assays. Equal amounts of ex-
tracted muscle proteins were separated on 8% polyacrylamide-SDS gels
at 40 mA for 50 min, and the protein was transferred to nitrocellulose fil-
ters. Blocked filters were incubated with 1:500 dilutions of either poly-
clonal anti-a7CDA (345), anti-a7CDB (347), or anti-b1D antibody. HRP-
linked anti–rabbit secondary antibody (Jackson ImmunoResearch Labo-
ratories) was used to detect primary antibodies. Immunoreactive protein
bands were detected using an ECL kit (Amersham Pharmacia Biotech).
Specificity of the bands was determined using the blocking peptides used
to raise the antibodies. Blots were reprobed with an anti-creatine kinase
antibody. The intensities of the a7 bands were compared with creatine ki-
nase and to total protein stained with Ponceau S using ImageQuant soft-
ware. Comparable results were obtained by both methods.
Southern Blot Analysis
Mouse genomic DNA was isolated from whole blood or liver using a ge-
nomic DNA isolation kit (Promega). DNA was cleaved with EcoRI and
KpnI at 3 U/mg of DNA for 16 h. DNA fragments were separated on 0.8%
agarose gels and alkaline transferred to Hybond-XL nylon membranes
(Amersham Pharmacia Biotech) (Sambrook et al., 1989). A 367-bp probe
from the rat a7 39-untranslated domain was isolated. The probe was di-
rectly labeled with HRP using a North2South nonradioactive kit (Pierce
Chemical Co.). The hybridized blots were washed following the manufac-
turer’s instructions. Probes were detected using an ECL substrate. Blots
were exposed to x-ray film for 1–30 min.
Immunofluorescence
Quadriceps muscles from 10-wk-old wild-type male mdx, mdx/utr2/2,  and
a7BX2-mdx/utr2/2 mice were embedded in OCT compound (Tissue-Tek)
and frozen in liquid nitrogen–cooled isopentane. Using a Leica CM1900 se-
ries cryostat, 10-mm sections were cut and placed on microscope slides coated
with 1% gelatin, 0.05% chromium potassium sulfate. Sections were fixed in
2208C acetone for 1 min, rehydrated in 13 PBS for 10 min, and blocked in
PBS containing 10% horse serum for 15 min. The rat a7 chain was detected
using 5 mg/ml of purified O26 monoclonal antibody directly labeled with Al-
exa 488 (Molecular Probes). The anti-b1D antibody was used at a 1:100 dilu-
tion in 1% horse serum in PBS. The antidystrophin antibody was used at a
1:100 dilution, whereas antiutrophin and anti-fMyHC antibodies were diluted
1:2 in 1% horse serum in PBS. Rhodamine-labeled a-bungarotoxin was used
at a 1:3,000 dilution to detect neuromuscular junctions (NMJs).
Endogeneous mouse immunoglobulin was blocked before the addition
of monoclonal antibodies using 60 mg/ml goat anti–mouse monovalent
Fabs (Jackson ImmunoResearch Laboratories) in 1% horse serum in PBS
for 30 min at room temperature. Slides were then washed three times for 5
min in 1% horse serum in PBS. Primary antibodies were added for 1 h at
room temperature. Slides were washed three times for 5 min in 1% horse
serum in PBS. Primary antibodies were detected with a 1:100 dilution of
FITC-labeled donkey anti–mouse or anti–rabbit antibody in 1% horse se-
rum in PBS. Slides were mounted using Vectorshield mountant (Vector
Laboratories). Localization of the antibody was observed with a ZEISS
Photomicroscope III. Images were acquired with a Sony DXC9000 color
video CCD camera using SiteCam software and a ZEISS Axiocam digital
camera (see Fig. 10).
Histology
10-mm cryosections from the quadriceps muscles of 5-, 8-, and 10-wk-old
wild-type, mdx, mdx/utr2/2, and transgenic mdx/utr2/2 mice were placed
on uncoated slides and stained with hematoxylin and eosin. The occur-
rence of central nuclei was scored in $1,000 fibers in two mice from each
line. The extent of mononuclear cell infiltration was estimated as the per-
centage of fields (403 objective) in which two or more clusters (.10 cells)
of mononuclear cells were detected. At least 80 fields in four sections
from each of the duplicate mice were scored.
Electron Microscopy
Sternomastoid muscles from 5-wk-old animals were fixed in 2% glutaral-
dehyde and 2.5% paraformaldehyde in 0.2 M Sorenson’s phosphate
buffer, embedded in LX-112 epoxy (Ladd Research Industries), sectioned
at 0.1 mm using a Reichert Ultracut E Ultramicrotome, stained with ura-
nyl acetate and lead citrate, and viewed with a Hitachi H-600 transmission
electron microscope at a 20,0003 magnification.
X-Ray and Magnetic Resonance Imaging
Spinal curvature (kyphosis) in 10-wk-old mdx, mdx/utr, and transgenic
a7BX2-mdx/utr2/2 mice was visualized by x-ray imaging using a Siemens
Heliodent 70 x-ray machine (model D3104). X-rays were taken at 70 kVp
and 7 mA. At least two mice of each genotype were analyzed.
Magnetic resonance imaging (MRI) of 10-wk-old wild-type, mdx,
mdx/utr2/2, and a7BX2-mdx/utr2/2 mice was used to visualize soft tis-
sues. Mice were imaged at 1-mm thickness using a 4.7 T/31 cm Surrey
Medical Imaging Spectrophotometer. At least two mice of each genotype
were analyzed.
Figure 1. Genotyping transgenic a7BX2-mdx/utr2/2 mice. (A)
The a7BX2 transgene (tg) was detected by PCR using primers
that amplify between the MCK promoter and the a7 cDNA se-
quence. Lanes 2 and 3 are positive for the MCK-a7BX2 trans-
gene. (B) Southern blot analysis using a rat a7-specific probe of
EcoRI- and KpnI-digested genomic DNA. The 7.1-kb band cor-
responding to the rat transgene construct is detected in lanes 4–6.
A higher 14.2-kb transgene dimer was also detected. Samples in
these lanes are from a7BX2-mdx/utr2/2 mice. DNA in lanes 1–3
are from nontransgenic mice. (C) Determining the status of the
utrophin gene by PCR. Only mutant utr alleles are detected in
lanes 1 and 4, identifying utr2/2 mice. One wild-type (wt) and one
mutant allele are amplified in lane 2, identifying a utr1/2 mouse.
Lane 3 is wild-type at both utr loci. (D) Determining the status of
the dystrophin gene by PCR. The mdx primer set detects the
point mutation in the dystrophin gene, whereas the wt primers
detect only the wild-type allele. Mouse 2 is wild-type at the dys-
trophin locus, mouse 3 is heterozygous (mdx/1), and mouse 4 is
mdx. Lane 1 contains no DNA.The Journal of Cell Biology, Volume 152, 2001 1210
Statistical Analysis
Survival data from 84 mdx/utr2/2 mice and 43 transgenic a7BX2-mdx/
utr2/2 mice were analyzed using the Kaplan-Meier method (Kaplan and
Meier, 1958). Survival curves were generated for both populations and
the data were compared using log-rank (Peto et al., 1977) and Wilcoxon
(Conover, 1980) statistical tests.
Online Supplemental Material
A video that contrasts kyphosis, gait, joint contractures, and mobility in
mdx/utr2/2 and a7BX2-mdx/utr2/2 mice can be viewed at http://www.jcb.org/
cgi/content/full/152/6/1207.
Results
Production of Transgenic Mice Expressing 
the Rat a7BX2 Chain
To test the hypothesis that the a7b1 integrin linkage sys-
tem can alleviate severe muscle disease, transgenic mice
were produced that express the rat a7 chain. DNA encod-
ing the rat a7 integrin a7BX2 isoform, under the tran-
scriptional control of the mouse MCK promoter, was
cloned and shown to have biological activity in vitro (Bur-
kin et al., 1998). The 3.3-kb MCK promoter limits tran-
scription to differentiated skeletal and cardiac muscle,
confining the effects of overexpression to these tissues
(Donoviel et al., 1996). The 7.1-kb construct, MCK-
a7BX2, was used to express the rat integrin in mdx/utr2/2
mice. Due to the mortality of the double knockout mice,
the rat transgene was initially introduced into a heterozy-
gous (mdx/utr1/2) background, and these animals were
then bred to produce double knockout transgenic off-
spring. The ratio of offspring followed expected Mende-
lian genetics, indicating that the transgenic expression of
the rat a7 integrin did not have an obvious effect on em-
bryonic development. Two independent lines of trans-
genic mice were produced: a7BX2#2 and a7BX2#9. In
this report, the data from the a7BX2#2 line are presented,
but similar results were obtained with both.
The presence of the rat a7 transgene was detected by
both PCR and Southern blot analyses. Using MCKI and
AATII primers, a 455-bp product was amplified only in
transgenic mice (Fig. 1 A). Southern blot analysis pro-
duced a strong 7.1-kb band only in transgenic mice. This is
the expected size of the EcoRI and KpnI digested MCK-
a7BX2 construct (Fig. 1 B). A weak 14.2-kb band was also
detected by Southern blot analysis, suggesting that a por-
tion of the constructs had lost one of these restriction sites.
The status of the utrophin gene was analyzed by PCR
using the primers 553, 554, and 22803 described previously
(Grady et al., 1997a). The 640-bp product is amplified
when the wild-type utrophin allele is present, whereas the
450-bp product is amplified when the utrophin mutant al-
lele is present (Fig. 1 C).
The status of the dystrophin gene was determined by
the amplification-resistant mutation detection system
(Amalfitano and Chamberlain, 1996). Using the mdx-spe-
cific primer set, a 275-bp mutant allele is detected, whereas
in separate reactions the wild-type–specific primer set de-
Figure 2. Expression of the rat
a7 protein in mouse muscle.
Immunofluorescence analy-
sis of hindlimb cryosections
using monoclonal antibodies
against the rat a7 integrin
chain, dystrophin, and utro-
phin. AChRs were stained
with rhodamine-labeled a-bun-
garotoxin to identify NMJs,
the sites of normal utrophin
localization. The rat a7 pro-
tein is only detected in trans-
genic mice and localizes to
the membrane of muscle fi-
bers. The lack of dystrophin
and utrophin in both trans-
genic and nontransgenic mdx/
utr2/2 mice confirms their
genotypes. The fluorescent
specks seen in the mdx/utr2/2
muscle stained with mouse
antidystrophin, antiutrophin,
and anti-a7 integrin antibodies
are also evident in the absence
of primary antibody and are
due to residual staining
with secondary anti–mouse
antibody.Burkin et al. Integrin-mediated Alleviation of Muscular Dystrophy 1211
tects a 275-bp wild-type allele. Fig. 1 D shows three differ-
ent genotypes at the dystrophin locus. Mouse 2 is wild-
type at the dystrophin locus, mouse 3 is heterozygous
(mdx/1), and mouse 4 is mdx.
Protein expression from the rat a7 chain transgene was
determined by immunofluorescence analysis of cryosec-
tions using the rat-specific a7 monoclonal antibody O26
(Fig. 2). The rat a7 chain was only detected by immunoflu-
orescence in the muscle of transgenic mice (Fig. 2). Immu-
nofluorescence also showed the absence of dystrophin in
muscle fibers and the absence of utrophin at NMJs in both
transgenic and nontransgenic mdx/utr2/2 mice (Fig. 2).
The fluorescent specks seen in Fig. 2 upon staining mdx/
utr2/2 muscle with mouse antidystrophin, antiutrophin,
and anti-a7 integrin antibodies are visible in the absence
of primary antibody and are due to residual staining with
secondary anti–mouse antibody.
The alternative spliced form of the b1 integrin chain,
b1D, is expressed in differentiated skeletal and cardiac
muscle (van der Flier et al., 1995; Zhidkova et al., 1995;
Belkin et al., 1996). Compared with the b1A, b1D may
form stronger linkages between the cell cytoskeleton and
extracellular matrix (Belkin et al., 1997). Immunofluores-
cence analysis showed b1A levels were elevated in fibers
of mdx/utr2/2 mice compared with wild-type and mdx ani-
mals. This is indicative of muscle that is not fully differen-
tiated. In contrast, a7BX2-mdx/utr2/2 mice had normal
levels of b1A integrin. Immunofluorescence and Western
blot analysis showed that mdx and mdx/utr2/2 mice have
more cell surface b1D chain than wild-type mice. This in-
crease in b1D coincided with an increase in endogenous
a7 chain in nontransgenic mdx and mdx/utr2/2 mice as
well as total a7 in a7BX2-mdx/utr2/2 mice. The a7BX2-
mdx/utr2/2 mice also had an additional 1.5-fold more b1D
compared with mdx/utr2/2 mice (Fig. 3 and Fig. 4 C). Thus,
an increase in the a7BX2b1D integrin is promoted by in-
creased expression of the a7 transgene.
As reported previously, mdx mice express approxi-
mately twofold more a7 integrin mRNA than wild-type
controls (Hodges et al., 1997). No further increase in a7
protein was detected in the mdx/utr2/2 animals. The
amount of a7BX2 protein in the a7BX2-mdx/utr2/2 mouse
hindlimb detected by Western blots was 2.0–2.3-fold
greater than the endogenous a7BX2 chain in mdx/utr2/2
Figure 3. Immunofluores-
cence of b1 integrin isoforms
in the hindlimb of 8-wk-old
wild-type,  mdx,  mdx/utr2/2,
and a7BX2-mdx/utr2/2 mice.
b1A integrin is elevated in
muscle fibers of mdx/utr2/2
mice compared with wild-
type and mdx animals. In con-
trast,  b1A levels are normal
in  a7BX2-mdx/utr2/2 mice.
Compared with wild-type, an
increase in b1D is detected in
both  mdx and mdx/utr2/2
muscle.  a7BX2-mdx/utr2/2
mice show an additional in-
crease in b1D compared with
both  mdx  and mdx/utr2/2
mice.The Journal of Cell Biology, Volume 152, 2001 1212
mice (Fig. 4, A and B). As expected, the levels of a7AX2
were equivalent in the transgenic and nontransgenic mice
(Fig. 4, A and B).
a7BX2-mdx/utr2/2 Mice Exhibit Increased 
Longevity and Mobility
Longevity was significantly extended in the a7BX2-mdx/
utr2/2 transgenic mice (Fig. 5). Kaplan-Meier survival anal-
ysis (Kaplan and Meier, 1958) of 84 nontransgenic and 43
transgenic mdx/utr2/2 mice demonstrated that the observed
differences in survival of these populations were statistically
significant (P , 0.001). Log-rank (Peto et al., 1977) and
Wilcoxon rank-sum tests (Conover, 1980) showed that the
difference in survival emerged soon after birth and was
maintained throughout the observed lifetime of the ani-
mals. The mdx/utr2/2 mice used in these experiments devel-
oped severe muscular dystrophy and 50% died before 12
wk of age. The median age at death of the transgenic mdx/
utr2/2 mice was 38 wk, a threefold increase over that ob-
served in nontransgenic mdx/utr2/2 littermates. These find-
ings were consistent in both male and female mice. The old-
est a7BX2-mdx/utr2/2 mouse was killed at 64 wk of age.
Compared with mdx mice that exhibit minimal pathol-
ogy, mdx/utr2/2 mice do not maintain weight. Instead,
these mice undergo a crisis period that results in weight loss
and premature death at 4–20 wk of age (Deconinck et al.,
1997b; Grady et al., 1997b). In contrast, a7BX2-mdx/utr2/2
transgenic mice did not show sudden weight loss. Animal
weight stabilized between 20 and 25 g (Fig. 6). No signifi-
Figure 4. Transgenic expression of a7BX2 increases the amount of
b1D in hindlimb muscle. (A) Western blot showing more a7B is
detected in transgenic mice compared with nontransgenic mice,
whereas a7A is constant. (B) The blots were reprobed with anti-
creatine kinase antibody. The creatine kinase levels were used to
normalize the amounts of a7A and a7B proteins in each sample.
The levels of a7A/creatinine kinase in both transgenic and non-
transgenic mice remained constant. In contrast, the a7B/creatinine
kinase ratio is 2.3-fold higher in the a7BX2 transgenic mice com-
pared with the nontransgenic animal. Comparisons relative to total
protein stained with Ponceau S indicate a 2.0-fold increase. (C)
b1D integrin from 8 wk hindlimb muscle. Less b1D is detected in
mdx/utr2/2 mice compared with a7BX2-mdx/utr2/2 mice. Com-
pared with total protein, an increase of approximately 1.5-fold
more b1D was detected in the transgenic versus nontransgenic
mice. Similar results were obtained in duplicate experiments.
Figure 5. Kaplan-Meier survival curves of 43 a7BX2-mdx/utr2/2
and 84 mdx/utr2/2 mice. Wilcoxon and log-rank tests show that
the a7BX2-mdx/utr2/2 and mdx/utr2/2  mice  populations have
distinct survival curves (P , 0.001). The a7BX2-mdx/utr2/2 mice
survive threefold longer than nontransgenic mdx/utr2/2 mice with
a median life expectancy of 38 wk. In contrast, nontransgenic
mdx/utr2/2 mice have a median life expectancy of 12 wk (95%
confidence intervals are indicated by shading).
Figure 6. Weight gain versus survival in five representative mdx/
utr2/2 mice and a7BX2-mdx/utr2/2 mice. The majority of non-
transgenic mdx/utr2/2 mice undergo a crisis at 5–10 wk of age that
results in a sudden loss of weight and premature death. Most
transgenic mdx/utr2/2 mice live longer and maintain weight.
Eventually these too will go through a crisis that results in weight
loss. The mean life span of the mdx/utr2/2 mice illustrated here is
10.4 wk; the mean life span of the a7BX2-mdx/utr2/2 mice illus-
trated here is 41.8 wk.Burkin et al. Integrin-mediated Alleviation of Muscular Dystrophy 1213
cant differences were found in the weights of mdx mice
compared with a7BX2-mdx mice 3–30 wk of age. Thus, ex-
tra a7BX2 chain itself does not promote weight gain.
By 8 wk of age, mdx/utr2/2 mice exhibited limited mo-
bility and a waddling gait. In contrast, a7BX2-mdx/utr2/2
littermates had highly improved mobility compared with
mdx mice. A video that contrasts kyphosis, gait, joint con-
tractures, and mobility in mdx/utr2/2 and a7BX2-mdx/
utr2/2 transgenic mice is accessible at http://www.jcb.org/
cgi/content/full/152/6/1207.
Enhanced Expression of the a7BX2 Chain Stabilizes 
Regeneration in mdx/utr2/2 Mice
Nuclei are normally localized along the periphery of myo-
fibers, whereas in regenerating muscle nuclei are cen-
trally located (DiMario et al., 1991). Regeneration is also
accompanied by a transient reversion to expression of fe-
tal isoforms of myosin heavy chain (fMyHC) (Matsuda et
al., 1983; Saad et al., 1987). Hindlimb sections from 5-, 8-,
and 10-wk-old wild-type, mdx, mdx/utr2/2, and a7BX2-
mdx/utr2/2 mice were stained with hematoxylin and eosin
to determine the extent of mononuclear infiltration and
centrally located nuclei (Fig. 7 and Table I). Immunoflu-
orescence of fMyHC was also determined. Degeneration
and regeneration that are characteristic of muscle disease
occur earlier in mdx/utr2/2 animals compared with mdx
mice (Fig. 7 and Table I). These results are consistent
with the earlier onset of necrosis and cell infiltration re-
ported previously in these animals (Deconinck et al.,
1997b; Grady et al., 1997b). The occurrence of central
nuclei in a7BX2-mdx/utr2/2 mice was similar to that in
mdx/utr2/2 mice, indicating that enhanced expression of
Table I. Percentage of Fibers with Central Nuclei
Mice 5 wk 8 wk 10 wk
Wild-type 2.6 1.3 2.7
mdx 33.0 65.6 70.9
mdx/utr2/2  79.0 78.4 75.3
a7BX2-mdx/utr2/2 62.1 71.7 63.9
Sections of hindlimb muscle from 5-, 8-, and 10-wk-old mice were stained with
hematoxylin and eosin. Nuclear localization was scored in $1,000 fibers in each animal.
Figure 7. Histology of hind-
limbs from 10-wk-old wild-
type, mdx, mdx/utr2/2, and
a7BX2-mdx/utr2/2 mice. He-
matoxylin and eosin (H & E)
staining reveals abundant cen-
tral nuclei in mdx, mdx/utr2/2,
and a7BX2-mdx/utr2/2 mice.
Mononuclear cell infiltration
(arrows) and expression of
fMyHC are extensive in the
mdx/utr2/2 mice, but are re-
duced in the a7BX2-mdx/
utr2/2 transgenic animals, in-
dicating less degeneration
and more stable regeneration
in these mice.The Journal of Cell Biology, Volume 152, 2001 1214
the integrin does not prevent early degeneration and re-
generation. Likewise, fMyHC expression was most ex-
tensive at 5 wk in the mdx/utr2/2 and a7BX2-mdx/utr2/2
mice. In contrast, mdx mice exhibited very little fMyHC
at 5 wk. At 8 wk, fMyHC was elevated in mdx mice, and
at 10 wk it was reduced, indicating that a cycle of degen-
eration and regeneration was followed by stabilization.
The shift from the b1A to b1D chain supports this con-
clusion. At all ages examined, the extent of fMyHC ex-
pression in the a7BX2-mdx/utr2/2 animals was interme-
diate between that found in the mdx and mdx/utr2/2
animals. In the 8- and 10-wk-old transgenic mdx/utr2/2
mice, fMyHC expression approached that in mdx mice
(Fig. 7). This decreased expression of fMyHC in a7BX2-
mdx/utr2/2 mice paralleled the greater integrity of tissue
seen in the 8- and 10-wk-old transgenic animals com-
pared with the mdx/utr (2/2) mice. The extensive mono-
nuclear cell infiltration observed in the mdx/utr2/2 mice
(89–97% positive fields) was also partially reduced in the
a7BX2-mdx/utr2/2 animals (Fig. 7). The percentage of
fields with cell infiltration was reduced approximately 17
and 19% in 5- and 8-wk-old transgenic versus nontrans-
genic  mdx/utr2/2  mice, respectively. This represents a
minimal estimate since the areas of cell infiltration were
considerably larger in the nontransgenic animals (Fig. 7).
Thus, enhanced expression of the a7b1 integrin does not
alter the initial degenerative cycle, but once regeneration
has taken place, the additional integrin appears to stabi-
lize muscle integrity, reducing muscle pathology.
Kyphosis and Joint Contractures Are Alleviated in 
a7BX2-mdx/utr2/2 Mice
Severe curvature of the spine (kyphosis) in DMD patients
and mdx/utr2/2 mice is due to a failure of the muscles that
would normally support the spinal column (Oda et al.,
1993). X-ray images showed that both kyphosis and rib
cage compression were markedly reduced in a7BX2-mdx/
utr2/2 mice compared with mdx/utr2/2 littermates (Fig. 8).
This was confirmed by whole body MRI which visualized
not only the tissues surrounding the spinal column, but
bundles of muscle fibers, the heart, lung, and other soft tis-
sues. The reduction in kyphosis promoted by the enhanced
expression of integrin in the a7BX2-mdx/utr2/2 animals is
likely a major factor in their survival. Kyphosis results in
the diaphragm being pushed forward, compromising lung
capacity and diaphragm function, and thereby contribut-
ing to cardiopulmonary failure. A partial reduction of ky-
phosis may therefore have dramatic effects on survival.
A hallmark of diseased musculature is the failure to ex-
tend limb muscles, resulting in joint contractures. Hind-
limb joint contractures are conspicuous in mdx/utr2/2 mice
but are markedly reduced in the a7BX2-mdx/utr2/2 mice
(Fig. 9). The reduction in hindlimb joint contractures al-
lows the mice to have greatly improved mobility.
Figure 8. X-ray and MRI of
normal and dystrophic mice.
Top three panels, the severe
spinal curvature (kyphosis)
and constriction of the rib
cage in mdx/utr2/2 mice are
largely reduced in the a7BX2
transgenic animals; bottom
four panels, MRI of midsagit-
tal sections reveals that ky-
phosis and reduction of pul-
monary volume in mdx/utr2/2
mice are largely alleviated in
transgenic mice.Burkin et al. Integrin-mediated Alleviation of Muscular Dystrophy 1215
Structural Changes in the NMJs of 
a7BX2-mdx/utr2/2 Mice
The NMJs in utr2/2 mice exhibit a significant reduction in
the number of synaptic folds and density of AChRs (De-
coninck et al., 1997a; Grady et al., 1997a). This is exacer-
bated in mdx/utr2/2 mice which show even greater reduc-
tion in postsynaptic folding and AChR density (Deconinck
et al., 1997b; Grady et al., 1997b). The postsynaptic plate of
the NMJ in the mdx/utr2/2 mice appears en face as discrete
boutons rather than as a continuous folded structure
(Grady et al., 1997b; Rafael et al., 2000).
Since the a7b1 integrin is normally found at NMJs
(Martin et al., 1996) and participates in the clustering of
AChRs in C2C12 cells (Burkin et al., 1998, 2000), we com-
pared the structure of NMJs from 5-wk-old wild-type,
mdx/utr2/2, and a7BX2-mdx/utr2/2 mice (Fig. 10). Longi-
tudinal sections of hindlimb muscles were stained with
rhodamine-labeled  a-bungarotoxin, and images of en face
sections of the postsynaptic membrane were analyzed.
Fluorescence staining of the NMJs of mdx/utr2/2 mice ap-
peared less intense compared with wild-type mice and
showed discrete boutons. In contrast, most NMJs from
a7BX2-mdx/utr2/2 mice appeared more continuous. The
postsynaptic membrane in longitudinal sections prepared
from sternomastoid muscles was examined by EM. The
normal folded morphology of the postsynaptic membrane
is markedly reduced in the mdx/utr2/2 animals, as reported
previously (Deconinck et al., 1997b; Grady et al., 1997b).
As seen in Fig. 10, postsynaptic folding was partially re-
stored in the a7BX2-mdx/utr2/2 mice. Thus, enhanced lev-
els of the a7b1 integrin help maintain the normal structure
of the NMJ.
Discussion
Our results demonstrate for the first time that enhanced
expression of the a7b1 integrin can alleviate the develop-
ment of muscular dystrophy and significantly extend lon-
gevity. Mice lacking both dystrophin and utrophin were
used in this study because in the absence of both proteins
direct substitution of dystrophin with utrophin is pre-
cluded. This results in the development of severe muscular
dystrophy and premature death, symptoms that closely re-
semble those seen in DMD (Deconinck et al., 1997b;
Grady et al., 1997b).
The a7BX2-mdx/utr2/2 mice reported here have z2.0–
2.3-fold more a7BX2 chain than their nontransgenic litter-
mates. The b1D chain, partner to a7, is also increased in
the a7BX2 transgenic mice. The increased levels of a7b1
integrin led to a threefold extension in median survival
time, markedly improved mobility, and reduced kyphosis
and joint contractures in the transgenic mdx/utr2/2 mice.
Kaplan-Meier survival analysis of the transgenic and non-
transgenic mdx/utr2/2 mice shows that the extension of
longevity due to expression of the transgene is statistically
significant and is evident early and throughout the life of
the animals.
The survival times of the mdx/utr2/2 mice in these ex-
periments differ slightly from those reported previously.
The original reported longevity of the mdx/utr2/2 mice
bred from the mdx/utr1/2 line used to produce the animals
in our experiments was 4–14 wk (Grady et al., 1997b).
More recently, a life span of 4–20 wk has been reported
(Grady et al., 1999) and occasional longer living mice have
been noted (Sanes, J.R., personal communication). We
too have noted some “outliers”: 6 of 84 mdx/utr2/2 mice
survived beyond 22 wk, with the oldest mouse dying at 36
wk of age. The transgenic and nontransgenic mice with ex-
tended life spans were reevaluated for expression of dys-
trophin and utrophin by PCR and immunofluorescence
and were again found deficient in both. Nevertheless,
a7BX2-mdx/utr2/2 mice are clearly distinct in longevity,
mobility, and histology from nontransgenic littermates.
The median life span of the a7BX2-mdx/utr2/2 mice was
38 wk, whereas the median life span for those not receiv-
ing the transgene was 12 wk.
Figure 9. Severe spinal curvature (kyphosis) and
hindlimb clasping (joint contractures) are largely re-
duced in mice expressing the rat a7BX2 transgene.The Journal of Cell Biology, Volume 152, 2001 1216
Although the mechanism by which enhanced expression
of the a7b1 integrin alleviates the development of the dys-
trophic phenotype is not currently understood, multiple
effects that result from additional a and b integrin chains
are possible.
Expression of the b1D chain is restricted to differenti-
ated skeletal and cardiac muscle (van der Flier et al., 1995;
Zhidkova et al., 1995; Belkin et al., 1996, 1997). In con-
trast, the b1A chain is present in a wide variety of cell
types including myogenic precursor cells. The b1D cyto-
plasmic domain may act to arrest the progression of myo-
blast proliferation and alter subcellular localization and af-
finity of a7b1 for its ligand and the association of the a7b1
with the cell cytoskeleton (Belkin et al., 1997). Therefore,
increased b1D expression in a7BX2 transgenic mice may
increase the interaction between the extracellular matrix,
sarcolemma, and the cell cytoskeleton, stabilizing muscle
integrity. Moreover, b1A, characteristic of nonmuscle cells
and undifferentiated muscle, is increased in mdx/utr2/2
and decreased in the transgenic mdx/utr2/2 animals. The
shift from b1A and increased b1D reflects fewer mononu-
clear cell infiltrates and increased stability of muscle fibers
in the rescued mice.
The a7BX2 integrin chain is normally concentrated at
neuromuscular and myotendinous junctions (Martin et al.,
1996) and at intrafascicular junctions (Duxson, M., per-
sonal communication). In patients with DMD and in mdx
and mdx/utr2/2 mice, endogenous expression of the a7 in-
tegrin protein is increased, and the a7BX2 isoform is also
found extrajunctionally (Hodges et al., 1997). This in-
crease in expression and redistribution of a7b1 integrin in
dystrophic mice is also seen with utrophin that is normally
confined to NMJs (Matsumura et al., 1992). Immunolocal-
ization of integrin encoded by the rat a7 transgene de-
tected with anti–rat a7 antibodies shows that the rat a7
protein is also distributed more globally in the a7BX2-
mdx/utr2/2 animals. Enhanced expression of the integrin
therefore contributes to the mechanical integration and
stability between muscle fibers and at their junctional
sites. Other possible mechanisms may also underlie how
the a7b1 integrin rescues mdx/utr2/2 mice.
Whereas the MCK promoter drives transcription in
skeletal and cardiac muscle (Donoviel et al., 1996), en-
hanced expression of the a7b1 integrin in the heart may
also contribute to the rescue of these animals. However,
expression of utrophin in skeletal muscle, but not cardiac
muscle, of mdx/utr2/2 mice increased survival and reduced
pathology (Rafael et al., 1998). These observations suggest
that the loss of skeletal muscle integrity is the major factor
in the development muscle pathology in mdx/utr2/2 mice.
The role of the a7b1 integrin in the formation of the
postsynaptic membrane (Burkin et al., 1998, 2000) suggests
Figure 10. Structure of the NMJ in 5-wk-old wild-type, mdx/utr2/2, and a7BX2-mdx/utr2/2 mice. (Left) En face views of AChRs in
the postsynaptic membrane detected with rhodamine-labeled a-bungarotoxin. In wild-type mice, the junctions appear continuous,
folded, and uninterrupted. In mdx/utr2/2 mice, the distribution of AChRs is discontinuous and organized into discrete boutons. The
organization of the postsynaptic membrane in a7BX2-mdx/utr2/2 transgenic mice has a more continuous (normal) pattern. (Right)
Ultrastructural changes in the NMJ. The postsynatic membrane of wild-type mice is highly folded (arrowheads). In contrast, mdx/
utr2/2 mice have little or no membrane folding. Expression of the a7BX2 transgene in mdx/utr2/2 mice results in a postsynaptic
membrane with partially restored folding (arrowheads). Bar, 1 mm.Burkin et al. Integrin-mediated Alleviation of Muscular Dystrophy 1217
that increased integrin expression may enhance the devel-
opment and stability of the NMJs. Dystrophin and utro-
phin are also concentrated at the postsynaptic membrane
and mdx, utr2/2, and mdx/utr2/2 mice show progressive al-
terations of the ultrastructure of these sites (Deconinck et
al., 1997b; Grady et al., 1997b). Whereas wild-type and
utr2/2 mice have NMJ endplates that are highly folded and
continuous, mdx and mdx/utr2/2 mice show discontinuous
NMJs that are described as discrete “boutons” (Grady et
al., 1997a,b; Rafael et al., 2000). Whereas both mdx and
utr2/2 mice show a reduction in the number of synaptic
folds compared with wild-type mice, mdx/utr2/2 mice show
even fewer synaptic folds (Deconinck et al., 1997b; Grady
et al., 1997b). Transgenic expression of the a7BX2 chain
appears to maintain the normal structure of the postsynap-
tic membrane in mdx/utr2/2 mice.
In the absence of dystrophin, there is an increase in total
muscle calcium (Bertorini et al., 1982) and an elevation of
intracellular calcium ([Ca21]i) in isolated dystrophic myo-
fibers (Turner et al., 1988). These increases have been at-
tributed to leaky calcium channels in dystrophic muscle
compared with normal muscle. The [Ca21]i increase may
activate Ca21-dependent proteolysis and increase muscle
degeneration (Denetclaw et al., 1994). [Ca21]i levels are
also regulated by signaling through the a7b1 integrin
(Kwon et al., 2000), suggesting that this integrin may
contribute to the maintenance of calcium levels in myofi-
bers. If so, the transgenic expression of the a7BX2 chain
may regulate the activity of calcium channels, stabilizing
[Ca21]i levels in mdx/utr2/2 myofibers and reducing Ca21-
dependent proteolysis and muscle degeneration.
Enhanced expression of the a7 integrin may contribute
to additional changes in the expression of other proteins,
both within the cell and in the extracellular matrix. For ex-
ample, matrix stability or modeling may potentiate both
mechanical and signal transduction capacities of muscle
(Colognato et al., 1999). This dual role for the integrin is
consistent with analyses of a72/2 mice. The myotendinous
junctions of fast fibers are compromised in a7-deficient
mice (Mayer et al., 1997). These myofibers also exhibit a
partial shift from b1D to b1A integrin and activation of
the c-Raf-1/mitogen-activated protein kinase 2 signaling
pathway. These changes cause a reduction of integrin-
dependent association of fibers and the basal lamina, con-
tributing to the dystrophy that develops in these mice (Sa-
her and Hildt, 1999). As shown here, increased a7 chain
leads to increased b1D.
A broad phenotype is seen in children with congenital
muscular dystrophies that arise from mutations in the a7
gene (Hayashi et al., 1998). These patients exhibit congen-
ital myopathy, delayed motor milestones, and severe im-
pairment of mobility. These phenotypes are consistent
with a role for a7b1 integrin in the formation and stability
of the postsynaptic membrane, myotendinous junctions,
and overall stability of muscle integrity.
Since enhanced expression of the a7b1 integrin can alle-
viate many of the symptoms of severe muscular dystrophy
in mdx/utr2/2 mice, it appears that the integrin- and dys-
trophin-mediated linkage systems between myofibers and
the extracellular matrix are in many ways functionally
complementary mechanisms. As such, the enhanced ex-
pression of the a7b1 integrin may be a novel approach to
alleviate DMD and treat a7 integrin congenital muscular
dystrophies. Moreover, increasing integrin levels may
prove effective in reducing the development of other mus-
cular dystrophies and cardiomyopathies that arise from
compromised expression of other components of the dys-
trophin glycoprotein complex.
This paper is dedicated to the memory of Dr. Kiichi Arahata, a distin-
guished scientist who taught us much about muscle and its diseases. 
We gratefully acknowledge the generous gift of the mdx/utr1/2 mice
provided by Dr. Joshua Sanes (Washington University) and the MCK
promoter and advice kindly provided by Drs. Stephen Hauschka and Jean
Buskin (University of Washington). We thank Dr. Jonathan Henry (Uni-
versity of Illinois) for his helpful discussions of the X-ray and MRI analy-
ses and Mr. Eric Chaney for his skillful assistance with the EM. Mice were
generated at the University of Illinois Transgenic Animal Facility under
the direction of Dr. Matt Wheeler, with the expert technical assistance of
Ms. Melissa Hentges. MRI data were obtained at the University of Illinois
Medical Resonance Imaging Center under the direction of Dr. Paul Lau-
terbur, with the technical assistance of Ms. Sherrie Frydenger. 
Supported by the Muscular Dystrophy Association and the National
Institutes of Health.
Submitted: 30 October 2000
Revised: 17 January 2001
Accepted: 22 January 2001
References
Amalfitano, A., and J.S. Chamberlain. 1996. The mdx-amplification-resistant
mutation system assay, a simple and rapid polymerase chain reaction-based
detection of the mdx allele. Muscle Nerve. 19:1549–1553.
Belkin, A.M., N.I. Zhidkova, F. Balzac, F. Altruda, D. Tomatis, A. Maier, G.
Tarone, V.E. Koteliansky, and K. Burridge. 1996. Beta 1D integrin displaces
the beta 1A isoform in striated muscles: localization at junctional structures
and signaling potential in nonmuscle cells. J. Cell Biol. 132:211–216.
Belkin, A.M., S.F. Retta, O.Y. Pletjushkina, F. Balzac, L. Silengo, R. Fassler,
V.E. Koteliansky, K. Burridge, and G. Tarone. 1997. Muscle beta1D integrin
reinforces the cytoskeleton–matrix link: modulation of integrin adhesive
function by alternative splicing. J. Cell Biol. 139:1583–1595.
Bertorini, T.E., S.K. Bhattacharya, G.M. Palmieri, C.M. Chesney, D. Pifer, and
B. Baker. 1982. Muscle calcium and magnesium content in Duchenne mus-
cular dystrophy. Neurology. 32:1088–1092.
Bulfield, G., W.G. Siller, P.A. Wight, and K.J. Moore. 1984. X chromosome-
linked muscular dystrophy (mdx) in the mouse. Proc. Natl. Acad. Sci. USA.
81:1189–1192.
Burkin, D.J., and S.J. Kaufman. 1999. The a7b1 integrin in muscle develop-
ment and disease. Cell Tissue Res. 296:183–190.
Burkin, D.J., M. Gu, B.L. Hodges, J.T. Campanelli, and S.J. Kaufman. 1998. A
functional role for specific spliced variants of the a7b1 integrin in acetylcho-
line receptor clustering. J. Cell Biol. 143: 1067–1075.
Burkin, D.J., J.E. Kim, M. Gu, and S.J. Kaufman. 2000. Laminin and a7b1 inte-
grin regulate agrin-induced clustering of acetylcholine receptors. J. Cell Sci.
113:2877–2886.
Campbell, K.P. 1995. Three muscular dystrophies: loss of cytoskeleton-extra-
cellular matrix linkage. Cell. 80:675–679.
Collo, G., L. Starr, and V. Quaranta. 1993. A new isoform of the laminin recep-
tor integrin alpha 7 beta 1 is developmentally regulated in skeletal muscle. J.
Biol. Chem. 268:19019–19024.
Colognato, H., D.A. Winkelmann, and P.D. Yurchenco. 1999. Laminin poly-
merization induces a receptor–cytoskeleton network. J. Cell Biol. 145:619–
631.
Conover, W.J. 1980. Practical Nonparametric Statistics. 2nd ed. John Wiley &
Sons, New York. 493 pp.
Deconinck, A.E., A.C. Potter, J.M. Tinsley, S.J. Wood, R. Vater, C. Young, L.
Metzinger, A. Vincent, C.R. Slater, and K.E. Davies. 1997a. Postsynaptic ab-
normalities at the neuromuscular junctions of utrophin-deficient mice. J.
Cell Biol. 136:883–894.
Deconinck, A.E., A.C. Potter, J.M. Tinsley, S.J. Wood, R. Vater, C. Young, L.
Metzinger, A. Vincent, C.R. Slater, and K.E. Davies. 1997b. Utrophin-dys-
trophin deficient mice as a model for Duchenne muscular dystrophy. Cell.
90:717–727.
Denetclaw, W.F., Jr., F.W. Hopf, G.A. Cox, J.S. Chamberlain, and R.A. Stein-
hardt. 1994. Myotubes from transgenic mdx mice expressing full-length dys-
trophin show normal calcium regulation. Mol. Biol. Cell. 5:1159–1167.
DiMario, J.X., A. Uzman, and R.C. Strohman. 1991. Fiber regeneration is not
persistent in dystrophic (mdx) mouse skeletal muscle. Dev. Biol. 148:314–
321.
Donoviel, D.B., M.A. Shield, J.N. Buskin, H.S. Haugen, C.H. Clegg, and S.D.
Hauschka. 1996. Analysis of muscle creatine kinase gene regulatory ele-
ments in skeletal and cardiac muscles of transgenic mice. Mol. Cell. Biol. 16:The Journal of Cell Biology, Volume 152, 2001 1218
1649–1658.
Grady, R.M., J.P. Merlie, and J.R. Sanes. 1997a. Subtle neuromuscular defects
in utrophin-deficient mice. J. Cell Biol. 136:871–882.
Grady, R.M., H. Teng, M.C. Nichol, J.C. Cunningham, R.W. Wilkinson, and
J.R. Sanes. 1997b. Skeletal and cardiac myopathies in mice lacking utrophin
and dystrophin: a model for Duchenne muscular dystrophy. Cell. 90:729–
738.
Grady, R.M., R.W. Grange, K.S. Lau, M.M. Maimone, M.C. Nichol, J.T. Stull,
and J.R. Sanes. 1999. Role for alpha-dystrobrevin in the pathogenesis of dys-
trophin-dependent muscular dystrophies. Nat. Cell Biol. 1:215–220.
Hayashi, Y.K., E. Engvall, Arikawa-Hirasawa, K. Goto, R. Koga, I. Nonaka, H.
Sugita, and K. Arahata. 1993. Abnormal localization of laminin subunits in
muscular dystrophies. J. Neurol. Sci. 119:53–64.
Hayashi, Y.K., F.-L. Chou, E. Engvall, M. Ogawa, C. Matsuda, S. Hirabayashi,
K. Yokochi, B.L. Ziober, R.H. Kramer, S.J. Kaufman, E. Ozawa, et al. 1998.
Mutations in the integrin a7 gene cause congenital myopathy. Nat. Genet.
19:94–97.
Hodges, B.L., and S.J. Kaufman. 1996. Developmental regulation and func-
tional significance of alternative splicing of NCAM and a7b1 integrin in
skeletal muscle. Basic Appl. Myol. 6:437–446.
Hodges, B.L., Y.K. Hayashi, I. Nonaka, W. Wang, K. Arahata, and S.J. Kauf-
man. 1997. Altered expression of the a7b1 integrin in human and murine
muscular dystrophies. J. Cell Sci. 110:2873–2881.
Hynes, R.O. 1992. Integrins: versatility, modulation, and signaling in cell adhe-
sion. Cell. 69:11–25.
Jaynes, J.B., J.S. Chamberlain., J.N Buskin, J.E. Johnson, and S.D. Hauschka.
1986. Transcriptional regulation of the muscle creatine kinase gene and re-
lated expression in transfected mouse myoblasts. Mol. Cell. Biol. 6:2855–
2864.
Johnson, J.E., B.J. Wold, and S.D. Hauschka. 1989. Muscle creatine kinase se-
quence elements regulating skeletal and cardiac muscle expression in trans-
genic mice. Mol. Cell. Biol. 9:3393–3399.
Kaplan, E.L., and P. Meier. 1958. Nonparametric estimation from incomplete
observations. J. Am. Stat. Assoc. 53:457–481.
Kim, Y.Y., C.S. Lim, Y.H. Song, J.H. Ahn, D.E. Park, and W.K. Song. 1999.
Cellular localization of a3b1 integrin isoforms in association with myofibril-
logenesis during cardiac myocyte development in culture. Cell Adhes. Com-
mun. 7:85–97.
Kwon, M.S., C.S. Park, K.-R. Choi, C.-S. Park, J. Ahnn, J.I. Kim, S.H. Eom, S.J.
Kaufman, and W.K. Song. 2000. Calreticulin couples calcium release and
calcium influx in a7b1 integrin-mediated calcium signaling. Mol. Cell. Biol.
11:1433–1443.
Law, D.J., D.L. Allen, and J.G. Tidball. 1994. Talin, vinculin and DRP (utro-
phin) concentrations are increased at the mdx myotendinous junctions fol-
lowing onset of necrosis. J. Cell Sci. 107:1477–1483.
Leung, E., S.P. Lim, R. Berg, Y. Yang, J. Ni, S. Wang, and G.W. Krissansen.
1998. A novel extracellular domain variant of the human integrin a7 subunit
generated by alternative intron splicing. Biochem. Biophys. Res. Commun.
243:317–325.
Lim, L.E., and K.P. Campbell. 1998. The sarcoglycan complex in limb-girdle
muscular dystrophy. Curr. Opin. Neurol. 11:443–452.
Martin, P.T., S.J. Kaufman, R.H. Kramer, and J.R. Sanes. 1996. Synaptic inte-
grins: selective association of the a1 and a7A, and a7B subunits with the
neuromuscular junction. Dev. Biol. 174:125–139.
Matsuda, R., D. Spector, and R.C. Strohman. 1983. Regenerating adult chicken
skeletal muscle and satellite cell cultures express embryonic patterns of my-
osin and tropomyosin isoforms. Dev. Biol. 100:478–488.
Matsumura, K., and K.P. Campbell. 1994. Dystrophin-glycoprotein complex: its
role in the molecular pathogenesis of muscular dystrophies. Muscle Nerve.
17:2–15.
Matsumura, K., J.M. Ervasti, K. Ohlendieck, S.D. Kahl, and K.P. Campbell.
1992. Association of dystrophin-related protein with dystrophin-associated
proteins in mdx mouse muscle. Nature. 360:588–591.
Mayer, U., G. Saher, R. Fassler, A. Bornemann, F. Echtermeyer, H. von der
Mark, N. Miosge, E. Poschl, and K. von der Mark. 1997. Absence of integrin
alpha 7 causes a novel form of muscular dystrophy. Nat. Genet. 17:318–323.
Monaco, A.P., R.L. Neve, C. Colletti-Feener, C.J. Bertelson, D.M. Kurnit, and
L.M. Kunkel. 1986. Isolation of candidate cDNAs for portions of the Du-
chenne muscular dystrophy gene. Nature. 323:646–650.
Oda, T., N. Shimizu, K. Yonenobu, K. Ono, T. Nabeshima, and S. Kyoh. 1993.
Longitudinal study of spinal deformity in Duchenne muscular dystrophy. J.
Pediatr. Orthop. 13:478–488.
Peto, R., M.C. Pike, P. Armitage, N.E. Breslow, D.R. Cox, S.V. Howard, N.
Mantel, K. McPherson, J. Peto, and P.G. Smith. 1977. Design and analysis of
randomized clinical trials requiring prolonged observation of each patient.
II. Analysis and examples. Brit. J. Cancer. 35:1–39.
Pons, F., A. Robert, J.F. Marini, and J.J. Leger. 1994. Does utrophin expression
in muscles of mdx mice during postnatal development functionally compen-
sate for dystrophin deficiency. J. Neurol. Sci. 122:162–170.
Rafael, J.A., J.M. Tinsley, A.C. Potter, A.E. Deconinck, and K.E. Davies. 1998.
Skeletal muscle-specific expression of a utrophin transgene rescues utro-
phin-dystrophin deficient mice. Nat. Genet. 19:79–82.
Rafael, J.A., E.R. Townsend, S.E. Squire, A.C. Potter, J.S. Chamberlain, and
K.E. Davies. 2000. Dystrophin and utrophin influence fiber type composi-
tion and post-synaptic membrane structure. Hum. Mol. Genet. 9:1357–1367.
Saad, A.D., T. Obinata, and D.A. Fischman. 1987. Immunochemical analysis of
protein isoforms in thick myofilaments of regenerating skeletal muscle. Dev.
Biol. 119:336–349.
Saher, G., and E. Hildt. 1999. Activation of c-Raf-1 kinase signal transduction
pathway in alpha(7) integrin-deficient mice. J. Biol. Chem. 274:27651–27657.
Sambrook, J., E.F. Fritsch, and T. Maniatis. 1989. Molecular Cloning: A Labo-
ratory Manual. 2nd ed., Vol. 2. Cold Spring Harbor Laboratory, Cold Spring
Harbor, NY. 9.45–9.46.
Shield, M.A., H.S. Haugen, C.H. Clegg, and S.D. Hauschka. 1996. E-box sites
and a proximal regulatory region of the muscle creatine kinase gene differ-
entially regulate expression in diverse skeletal muscles and cardiac muscle of
transgenic mice. Mol. Cell. Biol. 16:5058–5068.
Sicinski, P., Y. Geng, A.S. Ryder-Cook, E.A. Barnard, M.G. Darlison, and P.J.
Barnard. 1989. The molecular basis of muscular dystrophy in the mdx
mouse: a point mutation. Science. 244:1578–1580.
Song, W.K., W. Wang, R.F. Foster, D.A. Bielser, and S.J. Kaufman. 1992. H36-
a7 is a novel integrin alpha chain that is developmentally regulated during
skeletal myogenesis. J. Cell Biol. 117:643–667.
Song, W.K., W. Wang, H. Sato, D.A. Bielser, and S.J. Kaufman. 1993. Expres-
sion of a7 integrin cytoplasmic domains during skeletal muscle develop-
ment: alternate forms, conformational change, and homologies with serine/
threonine kinases and tyrosine phosphatases. J. Cell Sci. 106:1139–1152.
Tinsley, J.M., A.C. Potter, S.R. Phelps, R. Fisher, J.I. Trickett, and K.E. Davies.
1996. Amelioration of the dystrophic phenotype of mdx mice using a trun-
cated utrophin transgene. Nature. 384: 349–353.
Turner, P.R., T. Westwood, C.M. Regen, and R.A. Steinhardt. 1988. Increased
protein degradation results from elevated free calcium levels found in mus-
cle from mdx mice. Nature. 335:735–738.
van der Flier, A., I. Kuikman, C. Baudoin, R. van der Neut, and A. Sonnen-
berg. 1995. A novel beta 1 integrin isoform produced by alternative splicing:
unique expression in cardiac and skeletal muscle. FEBS Lett. 369:340–344.
Vignier, N., B. Moghadaszadehm, F. Gary, J. Beckmann, U. Mayer, and P.
Guicheney. 1999. Structure, genetic localization, and identification of the
cardiac and skeletal muscle transcripts of the human integrin alpha 7 gene
(ITGA). Biochem. Biophys. Res. Commun. 260:357–364.
von der Mark, H.J., J. Durr, A. Sonnenberg, K. von der Mark, R. Deutzmann,
and S.I. Goodman. 1991. Skeletal myoblasts utilize a novel a1-series integrin
and not a6b1 for binding to the E8 and T8 fragments of laminin. J. Biol.
Chem. 266:23593–23601.
Wang, W., W. Wu, T. Desai, D.C. Ward, and S.J. Kaufman. 1995. Localization
of the a7 integrin gene (ITGA7) on human chromosome 12q13: Clustering
of integrin and hox genes implies parallel evolution of these gene families.
Genomics. 26:563–570.
Zhidkova, N.I., A.M. Belkin, and R. Mayne. 1995. Novel isoform of beta 1 inte-
grin expressed in skeletal and cardiac muscle. Biochem. Biophys. Res. Com-
mun. 214:279–285.
Ziober, B.L., M.P. Vu, N. Waleh, J. Crawford, C.S. Lin, and R.H. Kramer.
1993. Alternative extracellular and cytoplasmic domains of the integrin a7
subunit are differentially expressed during development. J. Biol. Chem. 268:
26773–26783.